Guidelines for the use of bisphosphonates in bone metastases

European Journal of Cancer, Supplement

Volumn 1, Issue 6 SPEC. ISS., 2003, Pages 299-306

  Coleman, Robert ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IBANDRONIC ACID; METHOTREXATE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE METABOLISM; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG COATING; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG TOLERABILITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; MORBIDITY; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 5144232263     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)90034-6     Document Type: Conference Paper

References (30)

1. Coleman R.E., Rubens R.D. The clinical course of bone metastases in breast cancer. Br J Cancer. 55:1987;61-66
2. Neville-Webbe H., Holen I., Coleman R.E. The anti-tumour effects and potential of bisphosphonates. Cancer Treatments Reviews. 28:2002;305-320
3. Roodman G.D. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer. 97:(3):2003;733-738
4. Lipton A., Costa L., Ali S., et al. Use of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol. 4:(Suppl 11):2001;54-59
5. Jagdev S.P., Purohit O.P., Heatley S., Herling C., Coleman R.E. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 12:2001;1433-1438
6. Paterson A.H.G., Powles T.J., Kanis J.A., McCloskey E.V., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 11:1993;59-65
7. Kristensen B., Ejlertsen B., Groenvold M., et al. Oral clodronate in breast cancer patients with bone metastases: a randomised study. J Intern Med. 246:1999;67-74
8. van Holten-Verzantvoort A.T., Bijvoet O.L.M., Cleton F.J., et al. Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet. ii:1987;983-985
9. van Holten-Verzantvoort A.T., Kroon H.M., Bijvoet O.L.M., et al. Palliative bone treatment in patients with bone metastases from breast cancer. J Clin Oncol. 11:1993;491-498
10. Coleman R.E., Purohit O.P., Black C., et al. Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease. Ann Oncol. 10:1999;311-316
11. Tripathy D., Lazarev A., Lichinitser M.R., et al. Oral ibandronate lowers the incidence of skeletal complications in breast cancer patients with bone metastases. Proc Am Soc Clin Oncol. 21:2002;45a. (abstr 176)
12. Conte P.F., Mauriac L., Calabresi F., et al. Delay in progression of bone metastases treated with intravenous pamidronate: Results from a multicentre randomised controlled trial. J Clin Oncol. 14:1996;2552-2559
13. Hultborn R., Ryden S., Gunderson S., Holmberg E., Wallgren U.-B. Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial. Acta Oncol. 35:(suppl 5):1996;73-74
14. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases. N Engl J Med. 335:1996;1785-1791
15. Theriault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advance breast cancer and lyric bone lesions: A randomised, placebo-controlled trial. J Clin Oncol. 17:1999;846-854
16. Major P.P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy - a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 19:2001;558-567
17. Berenson J.R., Rosen L.S., Howell A., Porter L., Coleman R.E., Morley W., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 91:2001;1191-1200
18. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7:(5):2001;377-387
19. Coleman R.E., Rosen L.S., Gordon D., et al. Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis. Breast Cancer Res & Treat. 76:(suppl 1):2002;S95. (abs 355)
20. Body J.J., Lichinitser M.R., Diel I., et al. Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. Proc ASCO. 18:1999;575a
21. Plunkett T.A., Rubens R.D. Bisphosphonate therapy for patients with breast carcinoma: who to treat and when to stop. Cancer. 97:(suppl 3):2003;854-858
22. Brown J.E., Ellis S., Gutcher S., et al. The bone resorption marker Ntx is strongly correlated with skeletal events in metastatic bone disease and is influenced by dose escalation of clodronate. Proc Am Soc Clin Oncol. 21:2002;385a
23. Yoneda T., Michigami T., Yi B., et al. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev. 25:1999;293-299
24. Powles T., Paterson S., Kanis J.A., et al. Randomised, placebocontrolled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 20:2002;3219-3224
25. Diel U., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 339:1998;357-363
26. Diel I.J., Solomayer E., Gollan C., Schutz F., Bastert G. Bisphosphonates in the reduction of metastases in breast cancer - results of the extended follow-up of the first study population. [abstract] Proc Am Soc Clin Oncol. 20:2000;82a. (abstr 314)
27. Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of randomised controlled trial. J Clin Oncol. 19:2001;10-17
28. Van der Pluijm G, Vloedgraven H., van Beek E., et al. Bisphosphonates inhibit adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 98:1996;698-701
29. Jagdev S., Coleman R.E., Shipman C.M., Croucher P. The bisphosphonate zoledronic acid induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 84:2001;1126-1134
30. Wood J., Schnell C., Green J. Novel anti-angiogenic effects of the bisphosphonates compound zoledronic acid. JPET. 302:2002;1055-1061